 previous article in this issue | next article in this issue  |
|
Document Details : Title: Percutaneous mitral valve repair in high-risk patients: initial experience with the Mitraclip® system in Belgium Author(s): T. Vandendriessche , M. Kotrc , M. Tijskens , J. Bartunek , M. Delesie , B.P. Paelinck , D. De Bock , M. Penicka , B. Stockman , C. De Maeyer , C. Vrints , M. Vanderheyden , M.J. Claeys Journal: Acta Cardiologica Volume: 69 Issue: 3 Date: 2014 Pages: 265-270 DOI: 10.2143/AC.69.3.3027829 Abstract : Aims: Treatment with percutaneous edge-to-edge mitral valve repair (Mitraclip®) has recently been recommended as an alternative to conventional mitral valve repair for high surgical risk patients with symptomatic severe mitral regurgitation (MR). In this study, we report the first use of Mitraclip® therapy in Belgium. Methods and results: This prospective registry includes 41 consecutive patients treated with the Mitraclip® in two Belgian centres from October 2010 to June 2013. Acute procedural success, in-hospital safety end points and clinical status were analysed on an intention-to-treat basis up to one year after the procedure. In addition, determinants of major adverse cardiac events (MACE, death, surgical mitral valve intervention, and rehospitalization for heart failure) were analysed. Acute procedural success (successful clip placement and reduction of colour Doppler flow MR to ≤ 2) was obtained in 32 patients (78%) and 18 of these patients received two clips. The primary safety end point was reached in 36 pts (88%): one patient died due to intracranial bleeding, there were three urgent surgical interventions and one severe access site bleeding. The MACE rate after one year was 41% (17 patients). There were 11 deaths (27%), six surgical interventions (15%) and 10 rehospitalizations for heart failure (24%). Additional subgroup analysis revealed that the one-year MACE rate was particularly high in patients with left ventricular ejection fraction (LVEF) < 25%: 62% vs. 36% in patients with LVEF ≥ 25% (P = 0.05). At one year, MR ≤ 2+ and NYHA class ≤ 2 was present in 83% of the surviving patients. Conclusion: In high-risk patients with functional MR, treatment with the Mitraclip®-device is a feasible and safe option resulting in improvement of MR severity and clinical symptoms. However, as MACE is high in some subgroups (e.g. LVEF < 25%), careful patient selection is crucial to ensure the maximum benefit from this new technique. |
